Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition

Group 1 - Novo Nordisk announced the acquisition of Akero Therapeutics for up to $5.2 billion in cash, indicating a strategic move into the fatty liver disease treatment market [1] - This acquisition reflects Novo Nordisk's commitment to expanding its portfolio in the area of metabolic diseases, particularly focusing on non-alcoholic fatty liver disease (NAFLD) [1] - The deal is part of Novo Nordisk's broader strategy to enhance its offerings in chronic disease management, aligning with the growing demand for effective treatments in this therapeutic area [1]